OLMA
HealthcareOlema Pharmaceuticals, Inc.
$25.10
$-0.18 (-0.71%)
Jan 5, 2026
Price History (1Y)
Analysis
Olema Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $2.01 billion and approximately 122 employees. The company's industry-specific data is not available. The financial health of Olema Pharmaceuticals, Inc. indicates that the company has incurred significant losses, as evident from its net income (TTM) of -$149,956,992. Additionally, the company has negative EBITDA (-$159,963,008), free cash flow (-$71,390,752), and gross margin, operating margin, and profit margin of 0.0%. The return on equity is -59.2%, and the return on assets is -34.4%. Olema Pharmaceuticals, Inc.'s balance sheet shows a relatively low debt-to-equity ratio of 1.46 and a high current ratio of 8.03. The valuation context of Olema Pharmaceuticals, Inc. is marked by a negative forward price-to-earnings ratio (-10.78) and an EV/EBITDA ratio of -8.82. The company's price to book ratio is 5.60, which may indicate a possible overvaluation or undervaluation in relation to its assets.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Olema Pharmaceuticals, Inc.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $2.01B
- P/E Ratio
- N/A
- 52-Week High
- $36.26
- 52-Week Low
- $2.86
- Avg Volume
- 3.85M
- Beta
- 1.93
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 122